November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Talha Badar: A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
Apr 1, 2024, 23:39

Talha Badar: A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

 Talha Badar, Hematologist/Oncologist at Mayo Clinic, shared a post on X/Twitter:

“A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.

3+3 model with 4 INO dose levels: 0.3 mg/m2, 0.4 mg/m2, 0.5 mg/m2, and 0.6 mg/m2.

19 patients treated, dose-limiting toxicity (DLT) was thrombocytopenia.”

Talha Badar: A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

View the article attached to the post.
Source:  Talha Badar/X